



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN : L74899DL1978PLC009181

JPL/Stock-Corr-2013	February 12th, 2016
The Manager - Listing The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 Phone - 022 26598100	The Manager - Listing The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001. Phone - 022 22721233-34
CM Quote : JAGSNPHARM	Scrip Code : 507789


**SUBJECT : : UN-AUDITED FINANCIAL RESULTS FOR QUARTER/NINE MONTHS
ENDED 31.12.2015 & AUDITOR'S REPORT ON FINANCIAL RESULTS. (LIMITED
REVIEW)**

Dear Sir,

In terms of Clause 29, 47 and other applicable provisions of the Listing Agreement we are sending herewith Unaudited Financial Results for the quarter / nine months ended 31.12.2015. and Auditor's Report on financial Results. (Limited Review)

Thanking you.

Yours faithfully,
for JAGSONPAL PHARMACEUTICALS LIMITED


R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY



The Board of Director
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat
New Delhi - 110049

SUBJECT: LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED

We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") the Quarter ended 31.12.2015 which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the Quarter ended 31st, December 2015" (the "statement"). The statement has prepared by the Company pursuant to Regulation 33 of the SEBI, 2015 (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations 2015) which has been initialed by us for identification purposes.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagements to Review of Interim Financial Information Performed Independent Auditor of the entity" by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) rule 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO.,
Chartered Accountants



Place : New Delhi
Date : 12.02.2016

SURESH SETHI
PARTNER
F.R. No. 000632N
Membership No. 89318



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

Unaudited Financial Results for the Quarter ended 31.12.2015

Particulars	Rs. in lacs					
	3 months ended 31.12.2015 Unaudited	3 months ended 30.09.2015 Unaudited	3 months ended 31.12.2014 Unaudited	9 Months ended 31.12.2015 Unaudited	9 Months ended 31.12.2014 Unaudited	12 Months ended 31.03.2015 Audited
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	3461.07	3296.86	3242.86	10456.78	9930.23	13815.09
b Other Operating Income		30.94		30.94		0.00
Total Income from operations (net)	3461.07	3327.80	3242.86	10487.72	9930.23	13815.09
2 Expenses						
a Cost of materials consumed	1245.72	2164.71	1567.32	4720.45	4422.71	6383.36
b Purchases of stock-in-trade	357.38	267.62	50.18	742.40	606.89	649.48
c Changes in inventories of finished goods, work in progress	-338.86	-1147.36	-48.08	-979.13	-443.02	-164.55
d Employee benefits expenses	921.74	967.46	744.79	2712.80	2394.37	3211.33
e Depreciation and amortisation expense	74.22	73.08	71.76	216.44	214.66	270.69
f Other expenses	1031.01	825.27	742.01	2544.20	2226.03	2862.86
Total expenses	3291.21	3150.78	3127.98	9957.16	9421.64	13213.17
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	169.86	177.02	114.88	530.56	508.59	601.92
4 Other Income		3.41	0.41	6.31	5.55	11.10
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	169.86	180.43	115.29	536.87	514.14	613.02
6 Finance Cost	121.22	120.68	112.01	365.23	340.16	445.85
7 Profit from ordinary activities after finance cost but before Exceptional items (5-6)	48.64	59.75	3.28	171.64	173.98	167.17
8 Exceptional items						
9 Profit/(+)/Loss(-) from Ordinary Activities before tax (7+8)	48.64	59.75	3.28	171.64	173.98	167.17
10 Tax expense	13.73	15.90	0.66	46.33	63.66	50.06
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	34.91	43.85	2.62	125.31	110.32	117.11
12 Extraordinary Items (net of tax expense Rs. lacs)						
13 Net Profit/(+)/Loss(-) for the period(11-12)	34.91	43.85	2.62	125.31	110.32	117.11
14 Share of profit/(Loss) of associates						
15 Minority interest						
16 Net Profit/(Loss) after taxes, minority interest and share of	34.91	43.85	2.62	125.31	110.32	117.11
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr						7448.74
19.i Earnings Per Share (before extraordinary items)						
a. Basic (Rs.)	0.13	0.17	0.01	0.48	0.42	0.45
b. Diluted (Rs.)	0.13	0.17	0.01	0.48	0.42	0.45
19.ii Earnings Per Share (after extraordinary items)						
a. Basic (Rs.)	0.13	0.17	0.01	0.48	0.42	0.45
b. Diluted (Rs.)	0.13	0.17	0.01	0.48	0.42	0.45

Notes

- The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 12th February 2016. The Statutory Auditors have carried out a limited review of the aforesaid results.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.
- This full format of the Quarterly Financial Results is available on the stock exchange websites: www.nseindia.com and www.bseindia.com and on the Company's website www.jagsonpal.com
- Foreign Exchange Earning were Rs 144.88 lacs during the Quarter ending 31-12-2015. This Earning forms part of total Turnover of the company.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar

Rajpal Singh Kochhar
Managing Director
DIN No 00059492

Place : New Delhi
Date : 12.02.2016



Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

CIN No. L74899DL1978PLC009181